comparemela.com

Latest Breaking News On - Allogeneic cell therapy - Page 1 : comparemela.com

Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial

SEATTLE & CAMBRIDGE, Mass. & TOKYO, March 28, 2024 Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK s Allogeneic INKT Cell Therapy and Agenus Botensilimab and…

Trial is Supported by Stand Up To Cancer as Part of an Initiative to Find Treatments for the ~70% of Gastroesophageal Cancer (GEC) Patients for Whom Current…

With series A funds, IMU Bio s Cytatlas identifies cell types and immune signatures

IMU Biosciences Ltd. has raised £11.5 million (US$14.7 million) in a series A round to further develop and commercialize profiling technology that can identify from a blood sample which of more than 2,000 cell types are present in an individual’s immune system.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.